Quest announces availability of blood-based Alzheimer’s test

Key takeaways:

• The blood test uses plasma to detect two amyloid-beta biomarkers linked to the development of Alzheimer’s disease.
• Those who acquire the test can discuss results and formulate a care plan with a licensed physician.

Quest Diagnostics has announced the availability of a blood-based test that assesses the risk of developing Alzheimer’s disease through amyloid-beta biomarkers.

According to a press release from Quest, the AD-Detect Test for Alzheimer’s Disease, which can be purchased by consumers online, utilizes plasma from a single blood draw to evaluate levels of a pair of amyloid beta proteins — A42 and A40 — to help detect early signs consistent with devlopment and progression of AD.

More than 6 million Americans have been diagnosed with Alzheimer’s, the most prevalent form of dementia, with projections reaching as high as 14 million individuals by 2060, per the release.

According to statistics cited in the release, a research report from Quest, which was based on a Harris Poll survey, found that adult Americans want to be evaluated for dementia, including AD, nearly 10 years earlier than recommended. In addition, the company stated, 86% of adults polled believe blood tests for the early detection of AD risk will become routine for preventive care.

Individuals who acquire the new diagnostic will be able to discuss their results with a licensed physician, who can assist with a plan for continued care.

“Blood tests like AD-Detect hold incredible potential to make Alzheimer's disease risk assessment both accessible and convenient,” Michael K. Racke, MD, medical director of neurology at Quest Diagnostics, said in the release. “We're also seeing a push from consumers who have a desire to take more control of their health, including within more advanced areas like Alzheimer’s disease risk assessment.”